A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

NCT05979948 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Waldenström's Macroglobulinemia

Interventions

DRUG: Zanubrutinib
DRUG: Bendamustine
DRUG: Rituximab

Sponsor

Shanghai Changzheng Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]